Rating Overview and Context
On 02 Jan 2026, MarketsMOJO revised Astrazeneca Pharma India Ltd’s rating from 'Hold' to 'Sell', reflecting a significant change in the company’s overall assessment. The Mojo Score, a composite measure of quality, valuation, financial trend, and technical factors, declined by 12 points from 54 to 42. This score and rating encapsulate the current investment stance, signalling caution for investors considering exposure to this stock.
Here’s How Astrazeneca Pharma India Ltd Looks Today
As of 17 May 2026, Astrazeneca Pharma India Ltd is classified as a smallcap within the Pharmaceuticals & Biotechnology sector. The company’s financial and market data reveal a mixed picture, with certain strengths overshadowed by valuation concerns and subdued financial trends.
Quality Assessment
The company holds a good quality grade, indicating solid operational fundamentals and a respectable return on equity. Astrazeneca Pharma India Ltd’s return on equity (ROE) stands at 26.1%, which is a robust figure reflecting efficient capital utilisation and profitability relative to shareholder equity. This level of ROE is generally attractive to investors seeking companies with strong earnings generation capabilities.
Valuation Considerations
Despite the quality metrics, the stock is currently deemed very expensive. It trades at a price-to-book (P/B) ratio of 26.6, a significant premium compared to its peers and historical averages within the sector. This elevated valuation suggests that the market has priced in high growth expectations, which may not be fully supported by the company’s recent financial performance. The PEG ratio of 6.3 further emphasises that the stock’s price growth is outpacing earnings growth, signalling potential overvaluation risks for investors.
Financial Trend and Profitability
The financial trend for Astrazeneca Pharma India Ltd is currently flat. The latest quarterly results show a decline in profitability, with the profit after tax (PAT) for the quarter at ₹31.55 crores, down by 45.6% compared to the previous four-quarter average. Additionally, the company’s cash and cash equivalents have dropped to ₹399.94 crores, the lowest in the half-year period, and PBDIT (profit before depreciation, interest, and taxes) has also reached a quarterly low of ₹44.83 crores. These indicators point to a period of financial stagnation or mild deterioration, which may weigh on investor sentiment.
Technical Outlook
From a technical perspective, the stock is rated as mildly bearish. Price movements over recent months reflect some weakness, with the stock declining 4.36% over three months and 7.24% over six months. Year-to-date, the stock has fallen 5.75%, although it has delivered a positive 6.85% return over the past year. The one-day gain of 1.7% on 17 May 2026 suggests some short-term buying interest, but the overall technical signals remain cautious.
Implications for Investors
The current Sell rating indicates that Astrazeneca Pharma India Ltd may not be an attractive investment at present, primarily due to its stretched valuation and flat financial trends despite its good quality metrics. Investors should be wary of the premium pricing and consider whether the company’s future earnings growth justifies the current market expectations. The mildly bearish technical stance further suggests limited upside momentum in the near term.
For those holding the stock, this rating advises a careful review of portfolio exposure, while prospective investors might prefer to wait for more favourable valuation levels or clearer signs of financial improvement before committing capital.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Stock Performance Snapshot
Reviewing the stock’s recent price performance as of 17 May 2026, Astrazeneca Pharma India Ltd has experienced mixed returns. The one-day gain of 1.7% contrasts with a modest 0.03% increase over the past week and a slight 0.88% decline over the last month. Longer-term trends show a 4.36% drop over three months and a 7.24% decrease over six months. Year-to-date, the stock is down 5.75%, though it has managed a 6.85% gain over the last twelve months. These figures highlight a volatile but generally subdued price trajectory.
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, Astrazeneca Pharma India Ltd’s valuation stands out as notably high, which may reflect investor optimism about the company’s growth prospects or sector dynamics. However, the flat financial trend and recent profit declines suggest that the company is facing operational challenges that could temper future growth. Investors should weigh these factors carefully against sector peers and broader market conditions before making investment decisions.
Conclusion
In summary, Astrazeneca Pharma India Ltd’s current Sell rating by MarketsMOJO is grounded in a comprehensive evaluation of quality, valuation, financial trends, and technical indicators. While the company demonstrates strong quality metrics such as a high ROE, its very expensive valuation and flat financial performance present risks that investors should consider. The mildly bearish technical outlook further supports a cautious stance. This rating serves as a guide for investors to critically assess their positions and expectations regarding this stock in the current market environment.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
